Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. M. Nijland

Publicaties

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma

Development of an LC-MS/MS Method for Simultaneous Quantification of Ibrutinib and Ritonavir in Plasma and Dried Plasma Spots

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug–drug interactions

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study

Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study

Moving beyond R-CHOP in large B-cell lymphoma

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Pers/media

La consolidation de l’atezolizumab impressionne dans le DLBCL à haut risque

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 9 – Industrie, innovatie en infrastructuur

Meer informatie over de Sustainable Development Goals.